Search

everythinglearnresearchcommunity

for

Search:↓

Quality of life, overall survival, and progression-free survival should be equally prioritized in advanced breast cancer treatment decisions.

Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.

The AVET system effectively delivers genes to human keratinocytes and may help treat skin diseases.

Hair regrowth improved, but quality of life did not.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

5% ET-02 is a more effective and safe treatment for hair loss than current options.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.

Adding a second method to PROTACs could improve cancer treatment.

The treatment successfully reopened blood flow in most patients and extended the use of their dialysis access with low risk.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.

DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.

More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Both terazosin and baclofen effectively reduce pain in young men with chronic testicular pain, with no difference in their effectiveness.

ALRV5XR effectively increases hair density in men with androgenetic alopecia without adverse effects.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

Levetiracetam and valproate sodium both reduce seizures when added to lamotrigine, but levetiracetam has fewer side effects.

Intravenous corticosteroid therapy is effective for long-term hair regrowth in alopecia areata, and a scoring system helps predict treatment success and relapse.

Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.

Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.